Sino Biopharm hooks AstraZeneca, GSK for separate respiratory partnerships
Sino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday, AstraZeneca and GSK, for separate respiratory partnerships Topic Hubs AI drug discovery: News, analysis and interviews Antibody-drug conjugates: The next wave of targeted cancer drugs Biopharma M&A and dealmaking: Who’s buying and why Biopharma people moves: CEO changes, executive hires, board positions Biotech IPOs: Tracking the market for new public offerings Biotech venture funding: Who’s raising and where the money is going Cell and gene therapy manufacturing: Scaling the next frontier China biotech: Licensing deals and the Biosecure Act CRISPR and gene editing: The push…
Sino Biopharmaceutical announced drug development and sales pacts with two UK pharma companies on Wednesday.
One will see the Hong Kong biotech license an investigational PDE3/4 inhibitor to AstraZeneca for $200 ...
Source: Endpoints News